Conjunctival allergen challenge: Models in the investigation of ocular allergy

被引:53
作者
Abelson, MB [1 ]
Loeffler, O [1 ]
机构
[1] Ophthalm Res Associates, N Andover, MA 01845 USA
关键词
D O I
10.1007/s11882-003-0100-z
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Recently, the number of agents to treat ocular allergy has increased dramatically, from three (pheniramine, antazoline, cromolyn) to more than a dozen. A general increase in the incidence of atopy in recent years and the fact that patients are becoming less tolerant of bothersome signs and symptoms have been driving forces in this increase. As visual tasking, such as reading and working on a computer, has become more prevalent, there is an increased awareness of ocular allergy and the impact it has on quality of life and productivity at work and school. With the need for more effective medications, the development of models, such as the conjunctival allergen challenge (CAC), has made the identification of new agents more efficient. In this article, we review the relevant background on the science behind allergen challenges in the eye, how models are designed, and how models are used in the field today.
引用
收藏
页码:363 / 368
页数:6
相关论文
共 35 条
[1]   Histaminase activity in patients with vernal keratoconjunctivitis [J].
Abelson, MB ;
Leonardi, AA ;
Smith, LM ;
Fregona, IA ;
George, MA ;
Secchi, AG .
OPHTHALMOLOGY, 1995, 102 (12) :1958-1963
[2]  
ABELSON MB, 1983, ARCH OPHTHALMOL-CHIC, V101, P555
[3]  
ABELSON MB, 1988, OPHTHALMOLOGY, V95, P1494
[4]   Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model [J].
Abelson, MB .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (03) :211-218
[5]  
ABELSON MB, 1980, ARCH OPHTHALMOL-CHIC, V98, P856
[6]   Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis [J].
Abelson, MB .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 1999, 77 :38-42
[7]   CONJUNCTIVAL ALLERGEN CHALLENGE - A CLINICAL APPROACH TO STUDYING ALLERGIC CONJUNCTIVITIS [J].
ABELSON, MB ;
CHAMBERS, WA ;
SMITH, LM .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (01) :84-88
[8]   Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies [J].
Abelson, MB ;
Berdy, GJ ;
Mundorf, T ;
Amdahl, LD ;
Graves, AL .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2002, 18 (05) :475-488
[9]   EVALUATION OF THE NEW OPHTHALMIC ANTIHISTAMINE, 0.05-PERCENT LEVOCABASTINE, IN THE CLINICAL ALLERGEN CHALLENGE MODEL OF ALLERGIC CONJUNCTIVITIS [J].
ABELSON, MB ;
GEORGE, MA ;
SCHAEFER, K ;
SMITH, LM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (03) :458-464
[10]   Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity [J].
Abelson, MB ;
Spitalny, L .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (06) :797-804